Roche (OTCMKTS:RHHBY) Upgraded by Berenberg Bank to Buy

Berenberg Bank upgraded shares of Roche (OTCMKTS:RHHBYGet Rating) from a hold rating to a buy rating in a research note published on Wednesday, The Fly reports.

A number of other research firms also recently issued reports on RHHBY. Deutsche Bank Aktiengesellschaft dropped their price target on Roche from CHF 350 to CHF 325 and set a hold rating on the stock in a research report on Friday, July 22nd. Jefferies Financial Group upgraded Roche from a hold rating to a buy rating in a research report on Thursday, September 8th. Cowen reduced their target price on Roche from $58.00 to $48.00 and set an outperform rating on the stock in a research report on Monday, June 27th. Credit Suisse Group dropped their price objective on Roche from CHF 370 to CHF 350 and set a neutral rating for the company in a research note on Thursday, May 19th. Finally, Barclays lowered their target price on Roche from CHF 450 to CHF 400 and set an overweight rating for the company in a research note on Tuesday, July 19th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $260.14.

Roche Stock Up 0.1 %

Shares of OTCMKTS:RHHBY opened at $42.00 on Wednesday. The stock has a 50 day moving average of $41.57 and a 200 day moving average of $43.94. The company has a current ratio of 0.93, a quick ratio of 0.73 and a debt-to-equity ratio of 0.57. Roche has a 12-month low of $37.88 and a 12-month high of $53.86.

Institutional Trading of Roche

Several large investors have recently modified their holdings of RHHBY. Sofinnova Investments Inc. acquired a new stake in shares of Roche during the fourth quarter valued at about $70,764,000. Fisher Asset Management LLC raised its holdings in shares of Roche by 25.0% during the first quarter. Fisher Asset Management LLC now owns 5,823,906 shares of the company’s stock valued at $289,890,000 after buying an additional 1,165,391 shares during the last quarter. Cardinal Capital Management Inc. bought a new stake in shares of Roche during the first quarter valued at approximately $18,402,000. Todd Asset Management LLC raised its holdings in shares of Roche by 114.6% during the second quarter. Todd Asset Management LLC now owns 592,706 shares of the company’s stock valued at $24,722,000 after buying an additional 316,509 shares during the last quarter. Finally, Saratoga Research & Investment Management raised its holdings in Roche by 26.1% during the second quarter. Saratoga Research & Investment Management now owns 1,366,826 shares of the company’s stock worth $57,010,000 after purchasing an additional 283,119 shares in the last quarter. 0.23% of the stock is currently owned by institutional investors and hedge funds.

Roche Company Profile

(Get Rating)

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.

See Also

The Fly logo

Analyst Recommendations for Roche (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.